$42.07
2.39% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
NL0011606264
Symbol
MRUS
Sector
Industry

Merus N.V. Stock price

$42.07
-2.90 6.45% 1M
-18.13 30.12% 6M
+14.57 52.98% YTD
+13.50 47.25% 1Y
+10.10 31.59% 3Y
+26.70 173.72% 5Y
+32.03 319.02% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-1.03 2.39%
ISIN
NL0011606264
Symbol
MRUS
Sector
Industry

Key metrics

Market capitalization $2.88b
Enterprise Value $2.26b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 62.87
P/S ratio (TTM) P/S ratio 80.16
P/B ratio (TTM) P/B ratio 4.09
Revenue growth (TTM) Revenue growth -21.33%
Revenue (TTM) Revenue $35.93m
EBIT (operating result TTM) EBIT $-230.96m
Free Cash Flow (TTM) Free Cash Flow $-156.90m
Cash position $632.27m
EPS (TTM) EPS $-3.91
P/E forward negative
P/S forward 78.71
EV/Sales forward 61.73
Short interest 12.81%
Show more

Is Merus N.V. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Merus N.V. Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Merus N.V. forecast:

18x Buy
100%

Analyst Opinions

18 Analysts have issued a Merus N.V. forecast:

Buy
100%

Financial data from Merus N.V.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
36 36
21% 21%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 70 70
28% 28%
196%
- Research and Development Expense 192 192
29% 29%
533%
-228 -228
42% 42%
-636%
- Depreciation and Amortization 2.50 2.50
12% 12%
7%
EBIT (Operating Income) EBIT -231 -231
42% 42%
-643%
Net Profit -245 -245
38% 38%
-681%

In millions USD.

Don't miss a Thing! We will send you all news about Merus N.V. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Merus N.V. Stock News

Neutral
GlobeNewsWire
12 days ago
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®) for cancer, today announced that the first patient has been dosed in the Company's phase 2 trial evaluating petosemtamab monotherapy in heavily pretreated (3L+) metas...
Neutral
GlobeNewsWire
22 days ago
Petosemtamab in combination with pembrolizumab in 1L r/m PD-L1 expressing HNSCC ongoing with clinical data update planned for 2025
Neutral
GlobeNewsWire
24 days ago
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) [Merus, the Company, we, or our], a clinical-stage oncology company developing innovative, full-length, multispecific antibodies (Biclonics® and Triclonics®), announced today that the U.S. Food and Drug Administration (FDA) approved BIZENGRI® (zenocutuzumab-zbco), the first and only treatm...
More Merus N.V. News

Company Profile

Merus NV is a clinical-stage immune-oncology company, which engages in the discovery and development of bi-specific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg on June 16, 2003 and is headquartered in Utrecht, Netherlands.

Head office Netherlands
CEO Bill Lundberg
Employees 229
Founded 2003
Website www.merus.nl

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today